- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05313646
Clinical Evaluation for Batch Consistency of Ad5-nCoV in Chinese Healthy Adults
Safety, Immunogenicity, and Batch Consistency of a Single Dose of a Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine in Chinese Healthy Adults Aged 18 Years and Above: a Randomized, Double-blind, Parallel-controlled Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Lianyungang, Jiangsu, China, 222000
- Guanyun Center for Disease Control and Prevention
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- healthy participants aged 18 years and above who have not received COVID-19 vaccine.
- The subjects can provide with informed consent and sign informed consent form (ICF).
4. The subjects are able to and willing to comply with the requirements of the clinical trial program and could complete the follow-up of the study.
5. Axillary temperature ≤ 37.0℃. 6. negative IgM and IgG against SARS-CoV-2 7. with BMI between18.5 to 30.0 8. No history of epidemiological contact with COVID-2019 9. have not been to medium or high risk areas in the past 21 days and have no history of departure.
10. be determined to be healthy by medical history, physical examination and clinical examination and meet the requirements for immunization of this product.
Exclusion criteria:
- Medical history or family history of convulsion, epilepsy, encephalopathy and psychosis.
- Allergic to any component of the research vaccines, or a history of hypersensitivity or serious reactions to vaccination.
- Women with positive urine pregnancy test, pregnant or breast-feeding, or have a pregnancy plan in this study.
- Suffering from acute febrile disease, infectious disease, or SARS infection history
- Serious cardiovascular disease, such as arrhythmia, conduction block, myocardial infarction, severe hypertension, which cannot be controlled by medication (systolic blood pressure ≥180mmHg, diastolic blood pressure ≥110mmHg)
- Have severe chronic diseases or unstable condition ( Grade 3 or higher as defined in the guidelines for the classification of adverse events in clinical trials for prophylactic vaccines), Such as diabetes, thyroid disease and so on.
- Congenital or acquired angioedema / neuroedema.
- had urticaria one year before this vaccination.
- Asplenia or functional asplenia.
- Thrombocytopenia or other clotting disorder (this may contraindicate intramuscular injection).
- Faintng during acupuncture treatment
- Received immunosuppressant therapy, antiallergic therapy, cytotoxic therapy, high dose inhaled corticosteroid over the past 6 months (excluding corticosteroid spray for allergic rhinitis, surface corticosteroid for acute non-complicated dermatitis, and corticosteroid with dose less than 20mg/ day)
- Received blood products within 4 months before vaccination.
- Received other investigational drugs within 1 month prior to receiving the investigational vaccines.
- Received other live attenuated vaccines within 1 month prior to receiving the investigational vaccines.
- Received subunit or inactivated vaccine within 14 days prior to receiving investigational vaccine.
- Be receiving anti-tuberculosis treatment
- Have the history of SARS-CoV-2 infection or COVID-19
- Any medical, psychological, social or other conditions that, in the investigator's judgment, are inconsistent with the study protocol or affect the subjects' informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: batch 1 of Ad5-nCoV
Eligible subjects in both cohort were vaccinated with one injection of Ad5-nCoV, lot NCOV202101001.
|
The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202101001.
It contains 5×10^10 viral particles per 0.5 mL in a vial.
Other Names:
|
EXPERIMENTAL: batch 2 of Ad5-nCoV
Eligible subjects in both cohort were vaccinated with one injection of Ad5-nCoV, lot NCOV202101002.
|
The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202101002.
It contains 5×10^10 viral particles per 0.5 mL in a vial.
Other Names:
|
EXPERIMENTAL: batch 3 of Ad5-nCoV
Eligible subjects in both cohort were vaccinated with one injection of Ad5-nCoV, lot NCOV202102003.
|
The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202102003.
It contains 5×10^10 viral particles per 0.5 mL in a vial.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GMTs of SARS-CoV-2 RBD-specific binding IgG on day 28 after vaccination.
Time Frame: On day 28 after vaccination
|
GMTs of SARS-CoV-2 RBD-specific binding IgG on day 28 after vaccination.
|
On day 28 after vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of solicited adverse events within 7 days after vaccination.
Time Frame: Within 7 days after vaccination
|
Incidence of solicited adverse events within 7 days after vaccination.
|
Within 7 days after vaccination
|
Incidence of adverse reactions within 28 days after vaccination.
Time Frame: Within 28 days after vaccination
|
Incidence of adverse reactions within 28 days after vaccination.
|
Within 28 days after vaccination
|
GMFIs of SARS-CoV-2 RBD-specific binding IgG on day 28 after vaccination.
Time Frame: On day 28 after vaccination
|
GMFIs of SARS-CoV-2 RBD-specific binding IgG on day 28 after vaccination.
|
On day 28 after vaccination
|
Propotion of participants with at least four-fold increase of post-vaccination antibody level against SARS-CoV-2 RBD-specific binding IgG compared to that at baseline on day 28 after vaccination.
Time Frame: On day 28 after vaccination
|
Propotion of participants with at least four-fold increase of post-vaccination antibody level against SARS-CoV-2 RBD-specific binding IgG compared to that at baseline on day 28 after vaccination.
|
On day 28 after vaccination
|
GMTs of SARS-CoV-2 RBD-specific binding IgG on day 28 after vaccination stratified by neutralizing antibody levels against Ad5 at baseline.
Time Frame: On day 28 after vaccination
|
GMTs of SARS-CoV-2 RBD-specific binding IgG on day 28 after vaccination stratified by neutralizing antibody
|
On day 28 after vaccination
|
Incidence of unsolicited adverse events within 28 days after vaccination.
Time Frame: Within 28 days after vaccination
|
Incidence of unsolicited adverse events within 28 days after vaccination.
|
Within 28 days after vaccination
|
Incidence of serious adverse events (SAE) within the 6 months after vaccination.
Time Frame: Within the 6 months after vaccination
|
Incidence of serious adverse events (SAE) within the 6 months after vaccination.
|
Within the 6 months after vaccination
|
Collaborators and Investigators
Investigators
- Principal Investigator: Fengcai Zhu, MSc, Jiangsu Provincial Center for Diseases Control and Prevention
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JSVCT111
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on batch 1 of Ad5-nCoV
-
Jiangsu Province Centers for Disease Control and...Active, not recruiting
-
Jiangsu Province Centers for Disease Control and...Not yet recruiting
-
Fundación HuéspedDalhousie University; CanSino Biologics Inc.Active, not recruiting
-
Institute of Biotechnology, Academy of Military...Zhongnan HospitalCompleted
-
Jiangsu Province Centers for Disease Control and...Active, not recruiting
-
Jiangsu Province Centers for Disease Control and...Hunan Provincial Center for Disease Control and Prevention; Yunnan Center for... and other collaboratorsActive, not recruiting
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Recruiting
-
Fundación HuéspedCanSino Biologics Inc.; Canadian Center for Vaccinology; Hospital FernandezRecruiting
-
Institute of Medical Biology, Chinese Academy of...Yunnan Center for Disease Control and PreventionCompleted
-
Institute of Biotechnology, Academy of Military...Zhongnan Hospital; Jiangsu Province Centers for Disease Control and Prevention and other collaboratorsCompleted